Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	1.92	18.05	5.4	6.7	6.75
Revenue Growth (YoY)	-89.34%	234.40%	-19.42%	-0.76%	-3.96%
Cost of Revenue	1.28	3.43	1.49	0.3	-0.57
Gross Profit	0.64	14.62	3.91	6.4	7.32
Selling, General & Admin	10.3	20.71	24.66	19.76	11.61
Research & Development	13.78	31.31	59.84	32.19	11.76
Other Operating Expenses	3.91	0.04	1.55	27.29	1.34
Operating Expenses	27.99	52.06	86.04	79.24	24.71
Operating Income	-27.35	-37.44	-82.13	-72.84	-17.39
Interest Expense / Income	3.42	4.17	2.39	-0.05	0
Other Expense / Income	0.76	0.02	0.05	-6.5	-1.6
Pretax Income	-31.53	-41.63	-84.57	-66.29	-15.79
Income Tax	0.01	0.03	-0.2	-2.79	0.28
Net Income	-31.54	-41.66	-84.38	-63.5	-16.07
Shares Outstanding (Basic)	1	0	0	0	0
Shares Change	1943.58%	0.58%	49.94%	69.83%	26.84%
EPS (Basic)	-114.00	-1063.00	-2388.00	-2476.81	-806.40
EPS (Diluted)	-114.00	-1063.00	-2388.00	-2476.81	-806.40
Free Cash Flow	-30.81	-26.85	-71.01	-40.6	-19.4
Free Cash Flow Per Share	-38.44	-684.40	-1820.68	-1560.99	-1266.51
Gross Margin	33.26%	80.98%	72.38%	95.52%	108.39%
Operating Margin	-1421.57%	-207.41%	-1521.56%	-1087.37%	-257.67%
Profit Margin	-1639.50%	-230.78%	-1563.10%	-947.90%	-238.10%
Free Cash Flow Margin	-1601.51%	-148.72%	-1315.39%	-606.09%	-287.34%
EBITDA	-27.96	-37.29	-80.52	-64.5	-11.91
EBITDA Margin	-1452.96%	-206.60%	-1491.74%	-962.82%	-176.42%
Depreciation & Amortization	0.16	0.17	1.66	1.84	3.88
EBIT	-28.11	-37.46	-82.18	-66.34	-15.79
EBIT Margin	-1461.17%	-207.52%	-1522.43%	-990.33%	-233.95%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).